The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund announces the interim results of the study in Argentina on heterogeneous regimens combining Sputnik Light (the first component of the Russian Sputnik V vaccine against coronavirus) and vaccines produced by AstraZeneca (LSE: AZN), Sinopharm, Moderna (Nasdaq: MRNA) and Cansino. The study is co-sponsored by the Ministry of Health of Argentina and the RDIF.
The Sputnik Light vaccine is based on the human adenovirus serotype 26, the first component of Sputnik V. Interim results of the study in Argentina are based on data from 1,102 volunteers, and 12 various vaccine combinations. The overall design of the study will include 2,800 subjects – 560 in each of the 5 provinces of Argentina: City and Province of Buenos Aires, as well as Córdoba, La Rioja and San Luis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze